<DOC>
	<DOCNO>NCT03012191</DOCNO>
	<brief_summary>Recessive dystrophic epidermolysis bullosa ( RDEB ) incurable , devastate , inherit skin disease cause mutation COL7A1 gene encodes type VII collagen ( C7 ) , major component anchor fibril ( AFs ) , structure mediate epidermal-dermal adherence . Thirty percent RDEB patient nonsense mutation . The investigator recently demonstrate 5 patient intradermal topical gentamicin induce `` read-through '' nonsense mutation create robust sustain new C7 AFs dermal-epidermal junction ( DEJ ) skin also stimulate wound closure reduce new blister formation . No untoward side effect occur . Herein , investigator propose evaluate safety efficacy intravenous gentamicin patient . In theory , intravenous administration possibility treat simultaneously patient ' skin wound . The investigator also propose optimize concentration manner delivery topical gentamicin . The unambiguous milestone increase C7 AFs patient ' DEJ , improve EB Disease Activity Scores , absence significant gentamicin side effect .</brief_summary>
	<brief_title>Gentamicin Therapy Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Patients recessive dystrophic epidermolysis bullosa ( RDEB ) bona fide nonsense mutation COL7A1 gene assess genotyping RDEB patient nonsense mutation COL7A1 gene</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>